Print

HALO Healthcare Finalizes License Agreement With University of North Dakota for Cancer Detection Biomarkers  
7/23/2012 9:56:35 AM

IRVINE, Calif.--(BUSINESS WIRE)--HALO Healthcare, Inc., a provider of innovative diagnostic solutions for women’s breast care announced that it has signed a definitive license agreement with the University of North Dakota (UND) to develop biomarkers for the early detection of breast cancer. Early detection of breast cancer has significant health and economic benefits. The licensed UND technology is based on detecting cancer biomarkers in breast nipple aspirate fluid (NAF) which is the platform used for the HALO® Breast Test marketed by Halo Healthcare for breast cancer risk assessment. Over 25,000 HALO tests have been performed worldwide.
//-->